Triple
T391440
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Johnson & Johnson |
E8888
|
entity |
| Predicate | notableProduct |
P1448
|
FINISHED |
| Object |
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
|
E51059
|
NE FINISHED |
Provenance (5 batches)
| Stage | Batch ID | Job type | Status |
|---|---|---|---|
| creating | batch_69a2e7f55c60819097aff65ea2ca2832 |
elicitation | completed |
| NER | batch_69a2ec5d73e881909101308a583c8f13 |
ner | completed |
| NED1 | batch_69a4103bcd788190bbbe4ddf8f71171a |
ned_source_triple | completed |
| NED2 | batch_69a4134170008190a5a7d9567de6cc09 |
ned_description | completed |
| NEDg | batch_69a41108fce081908efb6b08dc0a7a63 |
nedg | completed |
Created at: Feb. 28, 2026, 1:08 p.m.